{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:09:10Z","timestamp":1776348550470,"version":"3.51.2"},"reference-count":54,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Ministry of Economic Affairs"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.044","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T01:45:58Z","timestamp":1526003158000},"page":"3584-3592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness"],"prefix":"10.1016","volume":"36","author":[{"given":"Piet A.","family":"van Rijn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieke A.","family":"Maris-Veldhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 G.P.","family":"van Gennip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.044_b0005","unstructured":"Theiler A. African horse sickness. Science Bulletin; 1921. p. 19."},{"key":"10.1016\/j.vaccine.2018.05.044_b0010","unstructured":"Mertens PPC, Maan S, Samuel A, Attoui H. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, editors. Virus Taxonomy VIIIth Report of the ICTV: Elsevier\/Academic Press London; 2005. p. 466\u2013483."},{"key":"10.1016\/j.vaccine.2018.05.044_b0015","first-page":"465","article-title":"Immunological types of horsesickness virus and their significance in immunization","volume":"27","author":"McIntosh","year":"1958","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2018.05.044_b0020","first-page":"139","article-title":"The isolation and identification of further antigenic types of African horsesickness virus","volume":"29","author":"Howell","year":"1962","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2018.05.044_b0025","doi-asserted-by":"crossref","first-page":"e1002477","DOI":"10.1371\/journal.ppat.1002477","article-title":"Identification and characterization of a novel non-structural protein of bluetongue virus","volume":"7","author":"Ratinier","year":"2011","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.vaccine.2018.05.044_b0030","doi-asserted-by":"crossref","first-page":"e25697","DOI":"10.1371\/journal.pone.0025697","article-title":"Detection of a fourth orbivirus non-structural protein","volume":"6","author":"Belhouchet","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.05.044_b0035","doi-asserted-by":"crossref","unstructured":"Erasmus BJ. The pathogenesis of African Horsesickness. In: Proceedings of the 3rd Int Conf Equine Infectious Diseases. Paris: Karger, Basel; 1973. p. 1\u201311.","DOI":"10.1159\/000393512"},{"key":"10.1016\/j.vaccine.2018.05.044_b0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/vr.101083","article-title":"Outbreaks of African horse sickness in Senegal, and methods of control of the 2007 epidemic","volume":"172","author":"Diouf","year":"2013","journal-title":"Veter Rec"},{"key":"10.1016\/j.vaccine.2018.05.044_b0045","first-page":"7","article-title":"The Transmission of Blue-Tongue andn Horse Sickness by Culicoides","volume":"19","author":"Du Toit","year":"1944","journal-title":"Onderstepoort J Vet Sci Animal Industry"},{"key":"10.1016\/j.vaccine.2018.05.044_b0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2915.2000.00245.x","article-title":"African horse sickness epidemiology: vector competence of South African Culicoides species for virus serotypes 3, 5 and 8","volume":"14","author":"Venter","year":"2000","journal-title":"Med Veter Entomol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2915.2007.00706.x","article-title":"Virus recovery rates for wild-type and live-attenuated vaccine strains of African horse sickness virus serotype 7 in orally infected South African Culicoides species","volume":"21","author":"Venter","year":"2007","journal-title":"Med Veter Entomol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrmicro1090","article-title":"Climate change and the recent emergence of bluetongue in Europe","volume":"3","author":"Purse","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0065","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1017\/S0950268809990367","article-title":"Assessing the impact of climate change on vector-borne viruses in the EU through the elicitation of expert opinion","volume":"138","author":"Gale","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2018.05.044_b0070","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/vr.161.16.564","article-title":"Potential new Culicoides vector of bluetongue virus in northern Europe","volume":"161","author":"Meiswinkel","year":"2007","journal-title":"Veter Rec"},{"key":"10.1016\/j.vaccine.2018.05.044_b0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00436-007-0519-6","article-title":"First occurrence of Culicoides obsoletus-transmitted Bluetongue virus epidemic in Central Europe","volume":"101","author":"Mehlhorn","year":"2007","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2018.05.044_b0080","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/vr.162.13.422-a","article-title":"Culicoides chiopterus as a potential vector of bluetongue virus in Europe","volume":"162","author":"Dijkstra","year":"2008","journal-title":"Veter Rec"},{"key":"10.1016\/j.vaccine.2018.05.044_b0085","doi-asserted-by":"crossref","first-page":"e23066","DOI":"10.1371\/journal.pone.0023066","article-title":"Transmission and control of African horse sickness in The Netherlands: a model analysis","volume":"6","author":"Backer","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.05.044_b0090","article-title":"Comparative risk analysis of two culicoides-borne diseases in horses: equine encephalosis more likely to enter france than african horse sickness","author":"Faverjon","year":"2016","journal-title":"Transboundary Emerg Dis"},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2018.05.044_b0095","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1099\/0022-1317-77-9-2053","article-title":"Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge","volume":"77","author":"Roy","year":"1996","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0100","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(01)00445-5","article-title":"The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant","volume":"20","author":"Scanlen","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.044_b0105","doi-asserted-by":"crossref","first-page":"e16503","DOI":"10.1371\/journal.pone.0016503","article-title":"A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR \u2212\/\u2212 mouse model","volume":"6","author":"Castillo-Olivares","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.05.044_b0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vetimm.2012.06.009","article-title":"An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses","volume":"149","author":"El Garch","year":"2012","journal-title":"Veter Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.05.044_b0120","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","article-title":"Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge","volume":"32","author":"Alberca","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.044_b0125","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00548-16","article-title":"Assembly of replication-incompetent African horse sickness virus particles: rational design of vaccines for all serotypes","author":"Lulla","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2017.06.023","article-title":"Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge","author":"Lulla","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.044_b0135","unstructured":"Potgieter AC, Wright IM, Erasmus BJ. Live attenuated African horsesickness virus WO 2016\/071850. Google Patents; 2014."},{"key":"10.1016\/j.vaccine.2018.05.044_b0140","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1128\/JVI.01052-15","article-title":"VP2 exchange and NS3\/NS3a deletion in African horse sickness virus (AHSV) in development of Disabled Infectious Single Animal vaccine candidates for AHSV","volume":"89","author":"van de Water SG, van Gennip RG, Potgieter CA, Wright IM, van Rijn PA","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0145","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12985-016-0574-7","article-title":"Requirements and comparative analysis of reverse genetics for bluetongue virus (BTV) and African horse sickness virus (AHSV)","volume":"13","author":"van Rijn PA, van de Water SG, Feenstra F, van Gennip RG","year":"2016","journal-title":"Virol J."},{"key":"10.1016\/j.vaccine.2018.05.044_b0150","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.vaccine.2018.03.003","article-title":"African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3\/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform","volume":"36","author":"van Rijn","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.044_b0155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virusres.2016.04.007","article-title":"African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro","volume":"220","author":"Faber","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.05.044_b0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0168-1702(95)00061-T","article-title":"The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses","volume":"38","author":"Laviada","year":"1995","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.05.044_b0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/1040841X.2016.1186005","article-title":"Current and next-generation bluetongue vaccines: requirements, strategies, and prospects for different field situations","volume":"43","author":"Feenstra","year":"2017","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0170","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/j.vaccine.2014.10.033","article-title":"VP2-serotyped live-attenuated bluetongue virus without NS3\/NS3a expression provides serotype-specific protection and enables DIVA","volume":"32","author":"Feenstra","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.044_b0175","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1016\/j.vaccine.2015.09.020","article-title":"Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue","volume":"33","author":"Tacken","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.044_b0180","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.vetmic.2009.01.033","article-title":"A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus","volume":"137","author":"Barros","year":"2009","journal-title":"Veter Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0185","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1016\/j.vaccine.2013.08.089","article-title":"Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: a genetic DIVA approach","volume":"31","author":"van Rijn PA, van de Water SG, van Gennip HG","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.044_b0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jviromet.2010.02.027","article-title":"Detection of Toggenburg Orbivirus by a segment 2-specific quantitative RT-PCR","volume":"165","author":"Hofmann","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.05.044_b0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jviromet.2006.05.028","article-title":"Rapid detection and quantitation of Bluetongue virus (BTV) using a Molecular Beacon fluorescent probe assay","volume":"137","author":"Orru","year":"2006","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.05.044_b0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1099\/0022-1317-82-1-149","article-title":"Variation of African horsesickness virus nonstructural protein NS3 in southern Africa","volume":"82","author":"van Niekerk","year":"2001","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0205","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s007050050132","article-title":"Nucleotide sequence comparison of the segments S10 of the nine African horsesickness virus serotypes","volume":"142","author":"Sailleau","year":"1997","journal-title":"Archiv Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0210","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/vir.0.83502-0","article-title":"Molecular epidemiology of the African horse sickness virus S10 gene","volume":"89","author":"Quan","year":"2008","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0215","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF01314778","article-title":"Persistent infection of BHK21\/WI-2 cells with rubella virus and characterization of rubella variants","volume":"54","author":"Sato","year":"1977","journal-title":"Archiv Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0220","first-page":"3","article-title":"Consensus sequence of 27 african horse sickness virus genomes from viruses collected over a 76-year period (1933 to 2009)","author":"Potgieter","year":"2015","journal-title":"Genome Announc"},{"key":"10.1016\/j.vaccine.2018.05.044_b0225","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/vr.122.22.536","article-title":"Detection of antibodies against African swine fever virus using infected monolayers and monoclonal antibodies","volume":"122","author":"Wensvoort","year":"1988","journal-title":"Vet Rec"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2018.05.044_b0230","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1099\/0022-1317-77-5-963","article-title":"Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus","volume":"77","author":"Britton","year":"1996","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0235","article-title":"Structural protein VP2 of African horse sickness virus is not essential for virus replication in vitro","volume":"91","author":"van Gennip RG, van de Water SG, Potgieter CA, van Rijn PA","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0240","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1040638712440986","article-title":"Sustained high-throughput polymerase chain reaction diagnostics during the European epidemic of Bluetongue virus serotype 8","volume":"24","author":"van Rijn","year":"2012","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.vaccine.2018.05.044_b0245","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1128\/JCM.00353-08","article-title":"False-positive results obtained when bluetongue virus serotype 1 Algeria 2006 was analyzed with a reverse transcription-PCR protocol for detection of epizootic hemorrhagic disease virus","volume":"46","author":"Aguero","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.044_b0250","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.rvsc.2008.07.015","article-title":"Rapid and sensitive detection of African horse sickness virus by real-time PCR","volume":"86","author":"Fernandez-Pinero","year":"2009","journal-title":"Res Veter Sci"},{"key":"10.1016\/j.vaccine.2018.05.044_b0255","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jviromet.2012.12.014","article-title":"Diagnostic accuracy of a duplex real-time reverse transcription quantitative PCR assay for detection of African horse sickness virus","volume":"189","author":"Guthrie","year":"2013","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.05.044_b0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/tbed.12100","article-title":"Bluetongue virus RNA detection by real-time rt-PCR in post-vaccination samples from cattle","volume":"62","author":"De Leeuw","year":"2015","journal-title":"Transboundary Emerg Dis"},{"key":"10.1016\/j.vaccine.2018.05.044_b0265","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1016\/j.vaccine.2010.06.034","article-title":"Bluetongue virus RNA detection by RT-qPCR in blood samples of sheep vaccinated with a commercially available inactivated BTV-8 vaccine","volume":"28","author":"Steinrigl","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.044_b0270","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1099\/vir.0.065615-0","article-title":"Bluetongue virus without NS3\/NS3a expression is not virulent and protects against virulent bluetongue virus challenge","volume":"95","author":"Feenstra","year":"2014","journal-title":"J General Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T18:28:28Z","timestamp":1571336908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18306649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":54,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18306649"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}